My first real exposure to what's commonly called augmented reality was about a year ago when one of my former colleagues introduced me to Pokemon Go. I remember her telling me that you could actually hold up your smartphone or tablet and see actual Pokemon along the street. Now fast forward by a year, and most of the hype surrounding the game has waned off. However there is still tremendous enthusiasm with augmented reality. In fact reality altering technology isn't just regulated to Pokemon and the video gaming industry, it has invaded health care and looks to be more...

Vascular Dynamics Inc. (VDI), a private company, said the FDA has approved an IDE application to initiate a pivotal trial for the Mobiushd system in the treatment of resistant hypertension. The Controlling and Lowering Blood Pressure with Mobiushd (CALM) 2 trial is a multicenter, prospective, randomized, double-blind, sham-controlled pivotal study.

Neural Analytics Inc. enrolled its first patient in a two-year study to develop a method for evaluating cerebral blood flow in patients with mild traumatic brain injury (TBI) using its Lucid M1 transcranial doppler ultrasound system. The Los Angeles-based private company's device is an all-in-one ultrasound system designed for measuring and displaying cerebral blood flow velocities of patients with brain disorders.

Neurostimulation specialist Nexeon Medsystems Inc. is looking to bring a nanoparticle-involved twist to the current popular narrative surrounding drug-coated balloons. The Dallas-based company is developing a nanocomposite-based polymer balloon with microperforations and was awarded an SBIR grant from the NIH. The grant will fund up to $600,000 of critical preclinical research and process development activities, including the completion of a pre-IDE meeting with the FDA.

Fresenius Medical Care AG & Co. has agreed to acquire home dialysis specialist Nxstage Medical Inc. for about $2 billion in a deal expected to close next year. The Bad Homburg, Germany-based company will offer $30 per share to acquire all of Nxstage's outstanding shares. This represents a 22 percent premium to Boston-based Nxstage's 90-day moving average share price.